Loading...

뉴스 목록

뉴스 목록

The third anti-tb drug was approved by the FDA

On August 14th, the FDA approved TB Alliance new fluorine-containing anti-tuberculosis drug Pretoman

더 읽어보세요 2019-09-23
Holiday Notice of Mid-Autumn Festival

To all departments and all employees:According to the related provisions on national holidays &

더 읽어보세요 2019-09-10
CPhI North America 2020 in Philadelphia USA Booth#1506
CPhI North America 2020 in Philadelphia USA Booth#1506

FluoroPharm will exhibit CPhI North America 2020 in Pennsylvania Convention Center,Philadelphia, PA,

더 읽어보세요 2019-08-26
FDA approves third oncology drug that targets a key genetic driver of cancer, rather than a specific type of tumor

The U.S. Food and Drug Administration today granted accelerated approval to Rozlytrek (entrectinib),

더 읽어보세요 2019-08-19
The 150 millionth chemical substance was born!

According to the American Chemical and Engineering News (C&EN), the American Chemical Abstracts

더 읽어보세요 2019-08-07
FDA approves Novartis Piqray® - the first and only treatment specifically for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer

Novartis today announced the US Food and Drug Administration (FDA) has approved Piqray® (alpelisib)

더 읽어보세요 2019-07-11
New drug delivery method, FDA approved a new epilepsy treatment

UCB announced that the USFDA has approved Nayzilam (midazolam) nasal spray for the acute treatment o

더 읽어보세요 2019-06-28
Holiday Notice of Dragon Boat Festival

To all departments and employees:According to the related national legal & the actual situation

더 읽어보세요 2019-05-31
Long-term anti-AIDS, Combination of two schemes submits application

On April 29, 2019,the anti-AIDS long-acting two-party “cabotegravir + Ripirilin”submitted to the FDA

더 읽어보세요 2019-05-28
For the initial treatment of HIV patients, the FDA approved the first dual-agent combination therapy

Today, the US FDA announced that it has approved the listing of the antiviral therapy Dovato (dolute

더 읽어보세요 2019-04-26